| Paul Jason Bradley, RN | |
|
920 Stanton L Young Blvd # Wp1140, Oklahoma City, OK 73104-5036 | |
| (405) 271-4351 | |
| (405) 271-8695 |
| Full Name | Paul Jason Bradley |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 6 Years |
| Location | 920 Stanton L Young Blvd # Wp1140, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003393802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 76375 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| O U Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ou Health Partners Inc | 5991105876 | 779 |
News Archive
How can we better diagnose blood diseases? A research group led by Helmholtz Munich aims to answer this question with artificial intelligence (AI).
Centers for Disease Control and Prevention has awarded $2 million to Duke University Prevention Epicenter as part of its program to conduct innovative research in the science of preventing Healthcare-Associated Infections, or HAIs, with the goal of saving lives in healthcare settings.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
Hard to Treat Diseases (the "Company") (HTDS.PK) provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.
A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.
› Verified 7 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
How can we better diagnose blood diseases? A research group led by Helmholtz Munich aims to answer this question with artificial intelligence (AI).
Centers for Disease Control and Prevention has awarded $2 million to Duke University Prevention Epicenter as part of its program to conduct innovative research in the science of preventing Healthcare-Associated Infections, or HAIs, with the goal of saving lives in healthcare settings.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
Hard to Treat Diseases (the "Company") (HTDS.PK) provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.
A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.
› Verified 7 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
How can we better diagnose blood diseases? A research group led by Helmholtz Munich aims to answer this question with artificial intelligence (AI).
Centers for Disease Control and Prevention has awarded $2 million to Duke University Prevention Epicenter as part of its program to conduct innovative research in the science of preventing Healthcare-Associated Infections, or HAIs, with the goal of saving lives in healthcare settings.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
Hard to Treat Diseases (the "Company") (HTDS.PK) provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.
A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Jason Bradley, RN Po Box 26901, Wp1140, Oklahoma City, OK 73126 Ph: (405) 271-4351 | Paul Jason Bradley, RN 920 Stanton L Young Blvd # Wp1140, Oklahoma City, OK 73104-5036 Ph: (405) 271-4351 |
News Archive
How can we better diagnose blood diseases? A research group led by Helmholtz Munich aims to answer this question with artificial intelligence (AI).
Centers for Disease Control and Prevention has awarded $2 million to Duke University Prevention Epicenter as part of its program to conduct innovative research in the science of preventing Healthcare-Associated Infections, or HAIs, with the goal of saving lives in healthcare settings.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
Hard to Treat Diseases (the "Company") (HTDS.PK) provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.
A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.
› Verified 7 days ago
Traci Renee Wilmarth, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9713 Lakecrest Dr, Oklahoma City, OK 73159 Phone: 405-213-5351 | |
Michael Sean O'dell, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 5501 N Portland Ave, Oklahoma City, OK 73112 Phone: 405-604-6000 | |
Mr. Darryl W. Jones, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1044 Sw 44th St, Oklahoma City, OK 73109 Phone: 405-431-9921 | |
Ivan Kozhulenko, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 920 Stanton L Young Blvd Ste Wp1140, Oklahoma City, OK 73104 Phone: 405-271-4351 Fax: 405-271-8695 | |
Robert Lee Rawls, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9600 Broadway Ext, Oklahoma City, OK 73114 Phone: 405-715-3610 Fax: 405-715-3612 | |
Jennifer A Thai, APRN - CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5501 N Portland Ave, Oklahoma City, OK 73112 Phone: 405-604-6000 |